



BioLineRx to Present at the 2020 Biotech Showcase

January 8, 2020

TEL AVIV, Israel, Jan. 8, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that management will provide a corporate update at the 2020 Biotech Showcase in San Francisco, California.

2020 Biotech Showcase Presentation Details:

Date: Tuesday, January 14, 2020

Time: 9:30 a.m. Pacific Time

Location: Hilton Union Square Hotel, San Francisco

Track: Yosemite A (Ballroom Level)

Webcast: [Link to webcast information](#)

The Company will also host institutional investor and partnering meetings at the 9th Annual LifeSci Advisors Corporate Access Event taking place in San Francisco, January 13-15, 2020.

To schedule a meeting with BioLineRx, investors can [register](#) on the online system managed by the Company's US investor relations firm, [LifeSci Advisors, LLC](#), or make a request via e-mail at Tim@lifesciadvisors.com.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

The Company's lead program, BL-8040, is a cancer therapy platform currently being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA[®] and chemotherapy under a collaboration agreement with MSD. BL-8040 is also being evaluated in a Phase 2b study in consolidation AML and a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation. In addition, the Company has an ongoing collaboration agreement with Genentech, a member of the Roche Group, evaluating BL-8040 in combination with Genentech's atezolizumab in two Phase 1b/2 solid tumor studies.

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being undergoing in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company's website at www.bioplinrx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on [Facebook](#), [Twitter](#), and [LinkedIn](#).

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 28, 2019. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contact:

Tim McCarthy

LifeSci Advisors, LLC

+1-212-915-2564

tim@lifesciadvisors.com

or

Tsipi Haitovsky

Public Relations

+972-52-598-9892

tsipihai5@gmail.com

 View original content: <http://www.prnewswire.com/news-releases/biolinerx-to-present-at-the-2020-biotech-showcase-300983409.html>

SOURCE BioLineRx Ltd.